It was reported on Tuesday that the European Commission has granted final approval to US-based companies Mylan (NASDAQ: MYL) and Pfizer Inc (NYSE: PFE) for the proposed combination of their Upjohn business.
The European Commission offered conditional approval in April 2020 that was subject to the divestiture of certain of Mylan's products in Europe.
The European Commission approved the proposed divestiture buyers and Mylan signed the contract with those customers on terms that the European Commission has accepted. Both firms have already received approval from the Australian Competition and Consumer Commission and the New Zealand Commerce Commission related to combining this business.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML